Patients requiring bone anabolic therapy with romosozumab should be treatment naïve per recent studies. Provincial formularies' interpretation of "treatment naïve" has been quite variable. A scientifically valid definition of "clinically treatment naïve" has been explored. Link to Article: https://link.springer.com/article/10.1007/s00198-026-07864-3

Denosumab Biosimilar Initiative Switch – August 29, 2024 to March 3, 2025 Many are aware that PharmaCare has switched coverage (with...

You may be eligible to participate in a study on virtual rehabilitation in addition to your standard therapy. See the poster below for...

Are you curious about biosimilar medications? According to Health Canada, a biosimilar is a biologic drug that closely matches an already...

Dr. David Kendler receives the 2024 Lindy Fraser Award on September 28, 2024

Dr. James Yeung and Dr. Raheem Kherani received UBC Innovation Award on September 27, 2024